Antibody engineering.
A century ago, in his private laboratory in Berlin, Paul Ehrlich conceived and developed the idea of using antibodies to target toxic molecules. Recent advances in genetic engineering have enormously extended the potential of this concept for the treatment of malignant diseases, by making it possible to isolate genes encoded for the antibody variable regions and to manipulate them to create new molecules.
George
A J
AJ
Department of Immunology, Royal Postgraduate Medical School, Hammersmith Hospital.
D000818:Animals; D000906:Antibodies / Q000032:analysis* / Q000276:immunology / Q000378:metabolism; D000911:Antibodies, Monoclonal; D005818:Genetic Engineering / Q000379:methods*; D006801:Humans; D008970:Molecular Weight; D011993:Recombinant Fusion Proteins
D000906:Antibodies; D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins